Table 2.
Associations between SATB2 expression and clinicopathological parameters in colorectal cancers
| Characteristic | Cohort 1 | Cohort 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total N | High | Low | Negative | p | Total N | High | Low | Negative | p | |
| All cases | 1329 (100%) | 1009 (76%) | 265 (20%) | 55 (4%) | 973 (100%) | 647 (67%) | 206 (21%) | 120 (12%) | ||
| Sex | ||||||||||
| Female | 618 (47%) | 451 (%) | 131 (%) | 36 (%) | 0.006 | 425 (44%) | 272 (42%) | 99 (48%) | 54 (45%) | 0.302 |
| Male | 711 (54%) | 558 (%) | 134 (%) | 19 (%) | 548 (56%) | 375 (58%) | 107 (52%) | 66 (55%) | ||
| Age (years) | ||||||||||
| <65 | 395 (30%) | 299 (30%) | 79 (30%) | 17 (31%) | 0.497 | 330 (34%) | 216 (33%) | 73 (35%) | 41 (34%) | 0.827 |
| 65–75 | 454 (34%) | 357 (35%) | 81 (31%) | 16 (29%) | 356 (37%) | 240 (37%) | 69 (34%) | 47 (39%) | ||
| >75 | 480 (36%) | 353 (35%) | 105 (40%) | 22 (40%) | 287 (29%) | 191 (30%) | 64 (31%) | 32 (27%) | ||
| Tumor location | ||||||||||
| Proximal colon | 532 (40%) | 352 (35%) | 139 (53%) | 41 (75%) | <0.001 | 321 (33%) | 179 (28%) | 81 (39%) | 61 (51%) | <0.001 |
| Distal colon | 399 (30%) | 338 (34%) | 55 (21%) | 6 (11%) | 205 (21%) | 146 (23%) | 43 (21%) | 16 (13%) | ||
| Rectum | 398 (30%) | 319 (32%) | 71 (27%) | 8 (15%) | 447 (46%) | 322 (50%) | 82 (40%) | 43 (36%) | ||
| Preoperative RT/CRT | ||||||||||
|
No Yes |
1091 (82%) 239 (18%) |
822 (82%) 187 (18%) |
217 (82%) 49 (18%) |
52 (95%) 3 (5%) |
759 (78%) 214 (22%) |
496 (77%) 151 (23%) |
164 (80%) 42 (20%) |
99 (83%) 21 (17%) |
0.301 | |
| AJCC disease stage | ||||||||||
| I | 246 (19%) | 212 (21%) | 27 (10%) | 6 (11%) | <0.001 | 213 (22%) | 155 (24%) | 40 (19%) | 18 (15%) | 0.156 |
| II | 485 (37%) | 375 (37%) | 90 (34%) | 21 (38%) | 306 (31%) | 201 (31%) | 64 (31%) | 41 (34%) | ||
| III | 425 (32%) | 306 (30%) | 102 (39%) | 17 (31%) | 346 (36%) | 229 (35%) | 75 (36%) | 42 (35%) | ||
| IV | 173 (13%) | 116 (12%) | 46 (17%) | 11 (20%) | 108 (11%) | 62 (10%) | 27 (13%) | 19 (16%) | ||
| Tumor grade | ||||||||||
| Low-grade | 1106 (83%) | 896 (89%) | 181 (68%) | 29 (53%) | <0.001 | 829 (85%) | 594 (92%) | 153 (74%) | 82 (68%) | <0.001 |
| High-grade | 223 (17%) | 113 (11%) | 84 (32%) | 26 (47%) | 144 (15%) | 53 (8%) | 53 (26%) | 38 (32%) | ||
| Lymphovascular invasion | ||||||||||
| No | 1043 (79%) | 813 (81%) | 187 (71%) | 43 (78%) | 0.002 | 509 (52%) | 356 (55%) | 102 (50%) | 51 (43%) | 0.028 |
| Yes | 286 (22%) | 196 (19%) | 78 (29%) | 12 (22%) | 464 (48%) | 291 (45%) | 104 (51%) | 69 (58%) | ||
| MMR status | ||||||||||
| pMMR | 1160 (87%) | 913 (90%) | 209 (79%) | 38 (69%) | <0.001 | 847 (87%) | 597 (92%) | 164 (80%) | 86 (72%) | <0.001 |
| dMMR | 169 (13%) | 96 (10%) | 56 (21%) | 17 (31%) | 126 (13%) | 50 (8%) | 42 (20%) | 34 (28%) | ||
| BRAF status | ||||||||||
| Wild-type | 1140 (86%) | 911 (91%) | 189 (71%) | 40 (73%) | <0.001 | 862 (89%) | 610 (94%) | 163 (79%) | 89 (74%) | <0.001 |
| Mutant | 187 (4%) | 96 (10%) | 76 (29%) | 15 (27%) | 111 (11%) | 37 (6%) | 43 (21%) | 31 (26%) | ||
Abbreviations: AJCC, The American Joint Committee on Cancer; RT/CRT, radiotherapy/chemoradiotherapy; MMR, mismatch repair; pMMR, mismatch repair proficient; and dMMR, mismatch repair deficient